Eli Lilly | Les Charges D'Exploitation



Operating Expenses Changement Date
AbbVie USD 16.59B 5.96B 2024-12
Abbott USD 9.06B 298M 2024-12
ALKERMES USD 267.3M 6.09M 2024-12
Amgen USD 6.78B 401M 2024-12
AstraZeneca USD 12.86B 2.06B 2024-12
Baxter International USD 3.19B 644M 2024-12
Biogen USD 2.01B 13.3M 2024-12
Bristol-Myers Squibb USD 11.55B 1.84B 2024-12
Drreddys Laboratories INR 64.87B 2.26B 2024-12
Eli Lilly USD 8.38B 1.53B 2024-12
Gilead Sciences USD 5.12B 1.54B 2024-12
GlaxoSmithKline GBP 7.42B 402M 2024-12
Glaxosmithkline GBP 7.42B 408M 2024-12
Indivior 213M 218M 2024-09
J&J USD 18.63B 500M 2024-12
Medtronic USD 6.65B 162M 2025-01
Merck USD 11.33B 1.4B 2024-12
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Novartis USD 11.28B 1.73B 2024-12
Novartis USD 10.15B 579M 2024-12
Novo Nordisk 37.49B 4.64B 2024-09
Perrigo USD 1.03B 13.4M 2024-12
Pfizer USD 18.17B 5.63B 2024-12
Prestige Brands USD 198.36M 1.09M 2024-12
Regeneron Pharmaceuticals USD 2.8B 26.53B 2024-12
Roche Holding CHF 11.43B 1.48B 2024-12
Sanofi EUR 10.07B 969M 2024-09
Sanofi EUR 10.52B 1.42B 2024-09
United Therapeutics USD 378.2M 27.6M 2024-12
Zoetis USD 1.59B 71M 2024-12



Eli Lilly Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.